Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
542
Recruiting Now
542
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT04137653 Phase 3
Recruiting
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoa...
Condition
Breast Cancer
Enrollment
1,498 pts
Location
China
Sponsor
Shengjing Hospital
NCT06485466 Phase 3
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Condition
Unresectable Hepatocellular Carcinoma
Enrollment
101 pts
Location
China
Sponsor
Guohui Xu
NCT05443737 Phase 3
Recruiting
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and You...
Condition
Cancer
Enrollment
2,800 pts
Location
United States
Sponsor
University of California, San
NCT05970172 Phase 3
Recruiting
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kid...
Condition
Chronic Kidney Disease
Enrollment
100 pts
Location
Belgium, Bulgaria, Croatia
Sponsor
Astellas Pharma Global Develop
NCT04794777 Phase 3
Recruiting
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatme...
Condition
Prostate Cancer
Enrollment
450 pts
Location
Sweden
Sponsor
Stefan Carlsson
NCT06127407 Phase 3
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chon...
Condition
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Enrollment
136 pts
Location
United States, Australia, Belgium
Sponsor
Servier Bio-Innovation LLC
NCT01954992 Phase 3
Recruiting
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Condition
Metastatic Pancreatic Adenocarcinoma
Enrollment
480 pts
Location
United States
Sponsor
Eleison Pharmaceuticals LLC.
NCT07200830 Phase 3
Recruiting
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA ...
Condition
Metastatic Castration-Resistant Prostate Carcinoma
Enrollment
1,524 pts
Location
United States
Sponsor
Alliance for Clinical Trials i
NCT05608200 Phase 3
Recruiting
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Condition
Hepatocellular Carcinoma Non-resectable
Enrollment
427 pts
Location
China
Sponsor
Second Affiliated Hospital of
NCT04943211 Phase 3
Recruiting
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose...
Condition
Histiocytosis
Enrollment
150 pts
Location
Poland
Sponsor
Anna Raciborska
NCT03952299 Phase 3
Recruiting
Oxybutynin for Post-surgical Bladder Pain and Urgency
Condition
Overactive Bladder Syndrome
Enrollment
100 pts
Location
United States
Sponsor
University of California, Davi
NCT06055257 Phase 3
Recruiting
Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradion...
Condition
Osteoradionecrosis
Enrollment
24 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen
NCT07464912 Phase 3
Recruiting
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Su...
Condition
Idiopathic Pulmonary Fibrosis (IPF)
Enrollment
508 pts
Location
China
Sponsor
Beijing Tide Pharmaceutical Co
NCT07010107 Phase 3
Recruiting
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
Condition
Reflux Esophagitis (RE)
Enrollment
500 pts
Location
China
Sponsor
Xuanzhu Biopharmaceutical Co.,
NCT03671044 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspens...
Condition
Triple Negative Breast Cancer
Enrollment
657 pts
Location
United States, India
Sponsor
Jina Pharmaceuticals Inc.
NCT07160244 Phase 3
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregn...
Condition
Healthy
Enrollment
6,000 pts
Location
United States, Argentina, Brazil
Sponsor
Pfizer
NCT06912698 Phase 3
Recruiting
Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasophar...
Condition
Nasopharyngeal Cancinoma (NPC)
Enrollment
342 pts
Location
China
Sponsor
Hai-Qiang Mai,MD,PhD
NCT04166409 Phase 3
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients Wit...
Condition
Low Grade Astrocytoma
Enrollment
170 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT07165028 Phase 3
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associ...
Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment
4,500 pts
Location
United States, Argentina, Australia
Sponsor
Eli Lilly and Company
NCT04161768 Phase 3
Recruiting
Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontan...
Condition
Spontaneous Bacterial Peritonitis
Enrollment
80 pts
Location
Egypt
Sponsor
Tanta University
NCT06867991 Phase 3
Recruiting
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Auto...
Condition
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Enrollment
200 pts
Location
China
Sponsor
The First People's Hospital of
NCT07738172 Phase 3
Recruiting
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligome...
Condition
Lung Neoplasms, Non-Small Cell Lung Cancer
Enrollment
154 pts
Location
Taiwan
Sponsor
National Taiwan University Hos
NCT05601700 Phase 3
Recruiting
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelia...
Condition
Carcinoma, Ovarian Epithelial
Enrollment
132 pts
Location
Italy
Sponsor
Ente Ospedaliero Ospedali Gall
NCT07378098 Phase 3
Recruiting
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroid...
Condition
Menorrhagia
Enrollment
254 pts
Location
South Korea
Sponsor
JW Pharmaceutical
NCT07217301 Phase 3
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Canc...
Condition
IO-resistant sqNSCLC
Enrollment
600 pts
Location
United States, China, Japan
Sponsor
Takeda
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology